{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:24:53Z","timestamp":1782516293582,"version":"3.54.5"},"reference-count":41,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Women's Health"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:p>A 2001 U.S. Government Accountability Office (GAO) report indicated 8 of 10 drugs withdrawn from the U.S. market between 1997 and 2000 posed greater risk to women than men. We examined drugs withdrawn from the market for safety-related reasons from January 1, 2001, to January 1, 2018. To be included, drugs must be listed as discontinued on Drugs@FDA and either listed in the Federal Register or cited in literature as being withdrawn for safety-related reasons. Biologics, over-the-counter products, and medical devices were excluded. During the 17-year time span, 19 drugs were withdrawn from the market for safety-related reasons, fewer drugs per year compared to the 3-year period examined in the GAO report. Food and Drug Administration (FDA) has not recommended the market removal of any drug approved since 2005 due to the time from the start of the Q wave to the end of the T wave (QT) interval prolongation resulting in torsades de pointes (TdP) or other abnormal heart rhythms. Furthermore, no drugs approved after the implementation of FDA's 2009 guidance on drug-induced liver injury (DILI) have been withdrawn because of hepatoxicity. All, but one of the drugs discontinued from the market for safety-related reasons during the period examined were approved between 1957 and 2002. TdP and DILI are two relevant examples of drug-induced adverse events posing greater risk to women than men. FDA has made measurable progress incorporating consideration of sex and gender differences into drug trial development and FDA review of these data, supporting inclusion of women in clinical trials, providing a comprehensive drug safety review, and advancing postmarket surveillance and risk assessment, thus strengthening FDA's ability to protect public health.<\/jats:p>","DOI":"10.1089\/jwh.2020.8380","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T11:40:43Z","timestamp":1614339643000},"page":"927-934","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Food and Drug Administration Beyond the 2001 Government Accountability Office Report: Promoting Drug Safety for Women"],"prefix":"10.1177","volume":"30","author":[{"given":"Marjorie R.","family":"Jenkins","sequence":"first","affiliation":[{"name":"Office of Women's Health, Office of the Commissioner, U.S. Food and Drug Administration, Silver Spring, Maryland, USA."},{"name":"University of South Carolina School of Medicine, Greenville, South Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica A.","family":"Munoz","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Bak","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Chai","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Ready","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin M.","family":"South","sequence":"additional","affiliation":[{"name":"Office of Women's Health, Office of the Commissioner, U.S. Food and Drug Administration, Silver Spring, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah L.","family":"Zinn","sequence":"additional","affiliation":[{"name":"Office of the Chief Scientist, Office of the Commissioner, U.S. Food and Drug Administration, Silver Spring, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbert","family":"Zusterzeel","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Woodcock","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"key":"e_1_3_5_2_2","volume-title":"Most drugs withdrawn in recent years had greater health risks for women","author":"Heinrich J","year":"2001","unstructured":"Heinrich J. Most drugs withdrawn in recent years had greater health risks for women. Washington, DC: U.S. Government Accountability Office-01-286R, 2001."},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.18549\/PharmPract.2016.01.708"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(00)00694-4"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00487.x"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra032426"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2016.09.013"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/0960327113512860"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-015-0251-9"},{"key":"e_1_3_5_10_2","volume-title":"Guideline for the format and content of the nonclinical pharmacology\/toxicology section of an application","author":"FDA","year":"1987","unstructured":"FDA. Guideline for the format and content of the nonclinical pharmacology\/toxicology section of an application. Silver Spring, MD: U.S. Department of Health and Human Services\u2013Food and Drug Administration Center for Drug Evaluation and Research. Guidance for Industry, 1987."},{"key":"e_1_3_5_11_2","volume-title":"Collection, analysis, and availability of demographic subgroup data for FDA-approved medical products. FDA report","author":"FDA","year":"2013","unstructured":"FDA. Collection, analysis, and availability of demographic subgroup data for FDA-approved medical products. FDA report. Silver Spring, MD: FDA, 2013."},{"key":"e_1_3_5_12_2","volume-title":"FDA action plan to enhance the collection and availability of demographic subgroup data","author":"FDA","year":"2014","unstructured":"FDA. FDA action plan to enhance the collection and availability of demographic subgroup data. Silver Spring, MD: FDA, 2014."},{"key":"e_1_3_5_13_2","unstructured":"FDA. Drug Trial Snapshots. [Cited March 1 2019]. Available at: https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ucm412998.htm Accessed January25 2021."},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2016.6272"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000177"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2012.3753"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.070"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3395"},{"key":"e_1_3_5_19_2","unstructured":"FDA. Potential Signals of Serious Risks\/New Safety Information Identified from the FDA Adverse Event Reporting System (FAERS). [Cited May 31 2019]. Available at: https:\/\/www.fda.gov\/drugs\/guidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/ucm082196.htm Accessed January25 2021."},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2017.08.009"},{"key":"e_1_3_5_21_2","unstructured":"FDA. Guidance for industry. Good pharmacovigilance practices and pharmacoepidemiologic assessment. March 2005. [cited September 20 2019]. Available at: www.fda.gov\/downloads\/regulatoryinformation\/guidances\/ucm126834.pdf Accessed September20 2019."},{"key":"e_1_3_5_22_2","first-page":"29","article-title":"5-Year trend of reporting adverse drug reaction: An Italian general practice experience","volume":"5","author":"Leone S","year":"2017","unstructured":"Leone S. 5-Year trend of reporting adverse drug reaction: An Italian general practice experience. EC Pharmacol Toxicol, 2017; 5:29\u201337.","journal-title":"EC Pharmacol Toxicol"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-9-217"},{"key":"e_1_3_5_24_2","first-page":"362","article-title":"Gender differences in healthcare utilization of patients with diabetes","volume":"18","author":"Kraemer HU","year":"2012","unstructured":"Kraemer HU, , Rueter G, , Schoettker B, et al. Gender differences in healthcare utilization of patients with diabetes. Am J Manag Care, 2012; 18:362\u2013369.","journal-title":"Am J Manag Care"},{"key":"e_1_3_5_25_2","unstructured":"FDA. Food and Drug Administration Amendments Act (FDAAA) of 2007. [Cited May 31 2019]. Available at: https:\/\/www.fda.gov\/regulatory-information\/selected-amendments-fdc-act\/food-and-drug-administration-amendments-act-fdaaa-2007 Accessed January25 2021."},{"key":"e_1_3_5_26_2","unstructured":"Sentinel. Active Risk Identification and Analysis (ARIA). [Cited May 31 2019]. Available at: https:\/\/www.sentinelinitiative.org\/active-risk-identification-and-analysis-aria"},{"key":"e_1_3_5_27_2","unstructured":"FDA. Sentinel System Five Year Strategy (2019\u20132023). January. 2019. [Cited May 31 2019]. Available at: https:\/\/www.fda.gov\/media\/120333\/download"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1307972"},{"key":"e_1_3_5_29_2","unstructured":"FDA. FDA Drug Safety Communication: FDA approves new label changes and dosing for zolpidem products and a recommendation to avoid driving the day after using Ambien CR. May 14 2013. [Cited May 31 2019]. Available at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-approves-new-label-changes-and-dosing-zolpidem-products-and Accessed January25 2021."},{"key":"e_1_3_5_30_2","unstructured":"FDA. Supplement Approval-NDA 021200\/S-015. [Cited May 31 2019]. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2019\/021200Orig1s015ltr.pdf"},{"key":"e_1_3_5_31_2","unstructured":"FDA. NDA\/BLA Multidisciplinary Review and Evaluation-NDA 021200 S-015. [Cited May 31 2019]; Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/021200Orig1s015MultidisciplineR.pdf"},{"key":"e_1_3_5_32_2","unstructured":"Drug products withdrawn or removed from the market for reasons of safety or effectiveness 21CFR216.24. 2018. Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=216.24 Accessed January29 2021."},{"key":"e_1_3_5_33_2","unstructured":"Additions and Modifications to the List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness 79 Fed. Reg. 37687 (July 2 2014). Available at: https:\/\/www.federalregister.gov\/documents\/2014\/07\/02\/2014-15371\/additions-and-modifications-to-the-list-of-drug-products-that-have-been-withdrawn-or-removed-from Accessed January29 2021."},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/2042098612454283"},{"issue":"4","key":"e_1_3_5_35_2","first-page":"iv16","article-title":"Drug-induced QT prolongation and proarrhythmia: An inevitable link?","volume":"9","author":"Ahmad K","year":"2007","unstructured":"Ahmad K, , Dorian P. Drug-induced QT prolongation and proarrhythmia: An inevitable link?. Europace, 2007; 9(Suppl 4):iv16\u2013iv22.","journal-title":"Europace"},{"key":"e_1_3_5_36_2","unstructured":"FDA. Aprotinin Injection (marketed as Trasylol) Information. 2008. [Cited July 16 2019]; Available at: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/aprotinin-injection-marketed-trasylol-information Accessed January25 2021."},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802395"},{"key":"e_1_3_5_38_2","unstructured":"Takeda Pharmaceuticals U.S.A. Inc. Withdrawal of Approval of a New Drug Application for OMONTYS (peginesatide) Injection 84 Fed. Reg. 3795 (February 13 2019)."},{"key":"e_1_3_5_39_2","first-page":"39406","article-title":"Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs; notice","volume":"58","author":"FDA","year":"1993","unstructured":"FDA. Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs; notice. Fed Regist, 1993; 58:39406.","journal-title":"Fed Regist"},{"key":"e_1_3_5_40_2","unstructured":"Applications for FDA Approval to Market a New Drug 21CFR314.50. Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=314.50 Accessed January29 2021."},{"key":"e_1_3_5_41_2","first-page":"61134","article-title":"International conference on harmonisation; guidance on E14 Clinical Evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; availability. notice","volume":"70","author":"FDA","year":"2005","unstructured":"FDA. International conference on harmonisation; guidance on E14 Clinical Evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; availability. notice. Fed Regist, 2005; 70:61134.","journal-title":"Fed Regist"},{"key":"e_1_3_5_42_2","first-page":"1","article-title":"Guidance for industry drug-induced liver injury: Premarketing clinical evaluation","volume":"28","author":"FDA","year":"2009","unstructured":"FDA. Guidance for industry drug-induced liver injury: Premarketing clinical evaluation. Drug Saf, 2009; 28:1\u201323.","journal-title":"Drug Saf"}],"container-title":["Journal of Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jwh.2020.8380","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jwh.2020.8380","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jwh.2020.8380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:52:50Z","timestamp":1777657970000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jwh.2020.8380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1089\/jwh.2020.8380"],"URL":"https:\/\/doi.org\/10.1089\/jwh.2020.8380","relation":{},"ISSN":["1540-9996","1931-843X"],"issn-type":[{"value":"1540-9996","type":"print"},{"value":"1931-843X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}